ArticleScientific reports2019
The Bacterial Product Violacein Exerts an Immunostimulatory Effect Via TLR8.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 46 citations in OpenAlex.
- Microbial pigments as multi-functional cosmeceuticals: mechanism of action and sustainable production.Archives of microbiology · 2026Review
- Violacein: a natural antibacterial agent empowered by film-forming sprays for topical applications.BMC complementary medicine and therapies · 2025Article
- Violacein-Loaded Outer Membrane Vesicles fromACS biomaterials science & engineering · 2025Article
- Bioconversion of a Dairy By-Product (Microorganisms · 2025Article
- Quorum quenching mediated biofilm impediment inHeliyon · 2024Article
- Regulation of virulence inFrontiers in microbiology · 2024Review
- Antitumor activity of natural pigment violacein against osteosarcoma and rhabdomyosarcoma cell lines.Journal of cancer research and clinical oncology · 2023Article
- Neuroprotective effects of violacein in a model of inherited amyotrophic lateral sclerosis.Scientific reports · 2022Article
- Characterization of Anti-Cancer Activities of Violacein: Actions on Tumor Cells and the Tumor Microenvironment.Frontiers in oncology · 2022Article
- Genome Analysis of theCurrent issues in molecular biology · 2021Article
- Recent Advances in Synthetic, Industrial and Biological Applications of Violacein and Its Heterologous Production.Journal of microbiology and biotechnology · 2021Review
- Multi-target drug with potential applications: violacein in the spotlight.World journal of microbiology & biotechnology · 2021Review
- Draft Genome Sequence of Janthinobacterium lividum ID1246, Isolated from a Rainbow Trout Hatchery Biofilm.Microbiology resource announcements · 2021Article
- Article
- Biotechnological Activities and Applications of Bacterial Pigments Violacein and Prodigiosin.Journal of biological engineering · 2021Review
- Production, purification, and process optimization of intracellular pigment from novel psychrotolerant Paenibacillus sp. BPW19.Biotechnology reports (Amsterdam, Netherlands) · 2021Article
- Assessment ofRSC advances · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Violacein, an indole-derived, purple-colored natural pigment isolated from Chromobacterium violaceum has shown multiple biological activities. In this work, we studied the effect of violacein in different immune cell lines, namely THP-1, MonoMac 6, ANA-1, Raw 264.7 cells, as well as in human peripheral blood mononuclear cells (PBMCs). A stimulation of TNF-α production was observed in murine macrophages (ANA-1 and Raw 264.7), and in PBMCs, IL-6 and IL-1β secretion was detected. We obtained evidence of the molecular mechanism of activation by determining the mRNA expression pattern upon treatment with violacein in Raw 264.7 cells. Incubation with violacein caused activation of pathways related with an immune and inflammatory response. Our data utilizing TLR-transfected HEK-293 cells indicate that violacein activates the human TLR8 (hTLR8) receptor signaling pathway and not human TLR7 (hTLR7). Furthermore, we found that the immunostimulatory effect of violacein in PBMCs could be suppressed by the specific hTLR8 antagonist, CU-CPT9a. Finally, we studied the interaction of hTLR8 with violacein in silico and obtained evidence that violacein could bind to hTLR8 in a similar fashion to imidazoquinoline compounds. Therefore, our results indicate that violacein may have some potential in contributing to future immune therapy strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.